Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Outline of Final Research Achievements |
Since discovering the MERS coronavirus (MERS-CoV) as a causative agent of severe respiratory illness in the middle east in 2012, a serological antibody testing has been conducted not only for assessing antibody responses of infected patients but also for investigating zoonotic origins of MERS-CoV. In this study, we developed a high-throughput virus neutralization assay using pseudotyped vesicular stomatitis virus (VSV)-bearing MERS-CoV S protein (MERSpv). In addition, we generated monoclonal antibody(MAb)against S protein, and developed an MAb-based competitive ELISA (cELISA) to detect MERS-CoV antibody. Both VSV pseudotype-based and cELISA are useful for the epidemiological investigation on MERS-CoV infection.
|